Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

NCT01529424 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia

Interventions

DRUG: ISIS apoC-III Rx
DRUG: ISIS apoC-III Rx
DRUG: ISIS apoC-III Rx
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.